Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A

Journal of the American College of Cardiology

Volumn 29, Issue 7, 1997, Pages 1474-1482

  Antman, E M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ADULT; ARTICLE; BLEEDING DISORDER; BLOOD CLOT LYSIS; CAPILLARY PERMEABILITY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; REVASCULARIZATION; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; THROMBOLYTIC THERAPY;

EID: 0030992622     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00094-6     Document Type: Article

References (29)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathophysiology of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50, 310-8.
2. Cairns J, Lewis HD Jr, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in coronary artery disease. Circulation. 95:1995;380S-400S.
3. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical practice guideline No. 10. AHCPR Publication No. 94-0602. Rockville (MD): Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services, 1994:154.
4. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation. 91:1995;2520-2527.
5. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 90:1994;61-68.
6. Ambrose J, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med. 156:1996;1382-1394.
7. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 88:1993;2045-2048.
8. Hirsh J, Levine M. Low molecular weight heparin. Blood. 79:1993;1-17.
9. Young E, Cosmi B, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost. 70:1993;625-630.
10. Barrowcliffe T, Johnson E, Thomas D. Low Molecular Weight Heparin. 1992;Wiley, Chichester.
11. Bounameaux H. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic disease. Goldhaber S. Fundamental and Clinical Cardiology. vol. 19:1994;323 Marcel Dekker, New York.
12. Blajchman M, Young E, Ofosu F. Effects of unfractionated heparin, dermatan sulfate, and low molecular weight heparin on vessel wall permeability in rabits. Ann NY Acad Sci. 556:1989;245-254.
13. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1374-1376.
14. Lensing A, Prins M, Davidson B, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med. 155:1995;601-607.
15. Enoxaparin. (RP 54563, Clexane,"Lovenox".) Investigator's Brochure. July 14, 1993.
16. Teien AN, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res. 8:1976;413-416.
17. Aiach M, Roncato M. Practical considerations on the measurement of low molecular weight heparin and anti-Xa activity. Semin Thromb Haemost. 11:1985;108-111.
18. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction results of the TIMI IIIB trial . Circulation. 89:1994;1545-1556.
19. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med. 319:1988;1105-1111.
20. Neri Serneri GG, Gensini GR, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet. 335:1990;615-618.
21. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users primary end points analysis from the ATACS trial . Circulation. 89:1994;81-88.
22. Nesvold A, Kontny F, Abildgaard U, Dale J. Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction a dose-finding study . Thromb Res. 64:1991;579-587.
23. Gurfinkel R, Mejail R, Durtonto E, et al. Heparina de bajo peso molecular en la angina inestable estudio piloto . Cardiol Intercontinental. 3:1994;83-86.
24. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 26:1995;313-318.
25. Low molecular weight heparin (Fragmin®) during instability in coronary artery disease (FRISC). Lancet. 347:1996;561-568.
26. Mätzsch T, Bergqvist D, Hedner U, Østergaard P. Effects of enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost. 57:1987;97-101.
27. Stiekema J, van Griensven J, van Dinther T, Cohen A. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. Br J Clin Pharm. 36:1993;51-56.
28. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 327:1992;141-145.
29. Granger CB, Miller JM, Bovil EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 91:1995;1929-1935.